EGFR and non-small cell lung carcinoma: Compensatory activation of mitogenic signals, such as MET, PIK3CA amplification, and MAPK/ERK signaling activation, counterbalances the inhibition of EGFR by TKI osimertinib in a significant portion of NSCLC patients (Leonetti et al., 2019).